More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$178.49B
EPS
3.62
P/E ratio
10.8
Price to sales
3.57
Dividend yield
2.871%
Beta
0.694454
Previous close
$40.30
Today's open
$39.76
Day's range
$39.53 - $40.55
52 week range
$35.12 - $64.16
show more
CEO
Maziar Mike Doustdar
Employees
68800
Headquarters
Bagsvaerd,
Exchange
New York Stock Exchange
Shares outstanding
4.43B
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
In a real-world study, semaglutide 2.4 mg once weekly injection was associated with a statistically significant mean weight loss from baseline, 18.9 lb (8.6 kg; ~8%), when compared to resmetirom at six months Semaglutide 2.4 mg was also associated with significantly greater reductions than resmetirom in AST and some cardiometabolic measures Additional real-world data from a separate analysis found people initiating semaglutide 2.4 mg had greater one-year reductions in liver enzymes and weight, plus a larger HbA1c decrease, versus those not initiating treatment with semaglutide 2.4 mg PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 6, 2026 /PRNewswire/ -- Novo Nordisk today announced new real-world data from PLATINUM-Truveta and RHODIUM-2, which are two retrospective studies evaluating associations between semaglutide 2.4 mg once weekly injection use versus those not initiating treatment with semaglutide 2.4 mg and liver and cardiometabolic outcomes in adults with metabolic dysfunction-associated steatohepatitis (MASH).
PRNewsWire • 17 hours ago

Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income
Novo Nordisk A/S is upgraded to Strong Buy, driven by robust Q3 results and accelerating Wegovy pill adoption. Novo Nordisk trades at just 7.8x trailing operating income, well below pharma peers, supporting a value-driven investment thesis. Projected annualized returns exceed 18% through 2030, underpinned by expanding oral GLP-1 market share and pipeline momentum.
Seeking Alpha • Nov 6, 2026

NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook
Novo raises its 2026 outlook as Wegovy pill adoption accelerates, while Medicare-driven demand, pricing pressures and 2027 growth remain in focus.
Zacks Investment Research • Nov 5, 2026

Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
Obesity drugmaker Novo Nordisk raised its 2026 outlook for the third time this year on Wednesday as quarterly sales of its Wegovy pill beat forecasts, bolstering the Danish firm's efforts to recover ground lost to US rival Eli Lilly.
Reuters • Nov 4, 2026

Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S.
WSJ • Nov 4, 2026

Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know
Novo Nordisk raised its 2026 outlook for the second time in three months, and the stock jumped about 5% on Wednesday. CEO Mike Doustdar wouldn't forecast 2027, but he listed three things helping next year's sales and three hurting them.
The Motley Fool • Nov 4, 2026

Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone
Novo Nordisk shares surged Wednesday on a single metric from the Wegovy earnings call that suggested the oral pill is reshaping the obesity market faster than Wall Street expected, even as prices fall and a rival closes in.
24/7 Wall Street • Nov 4, 2026

Novo Nordisk stock jumps as Wegovy pill sales beat estimates
Novo Nordisk shares NVO rallied on Wednesday after the Danish drugmaker reported stronger-than-expected third-quarter results, driven by demand for its Wegovy weight-loss pill, and raised its full-year outlook for the third time this year. The company's American depositary receipts rose as much as 5.36% to $42.36, recovering some ground after falling more than 20% this year through Tuesday's close.
Invezz • Nov 4, 2026

Novo Nordisk's CFO Karsten Munk Knudsen to leave company
Novo Nordisk said on Wednesday its Chief Financial Officer Karsten Munk Knudsen would step down and that Luigi La Corte would join as its new CFO.
Reuters • Nov 4, 2026

Novo Nordisk: 3 Key Takeaways for Long-Term Investors
Novo Nordisk added 1.3 million patients in the third quarter. Wegovy pill will reach over 20 markets by mid-2027.
The Motley Fool • Nov 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Novo Nordisk A/S commission-free¹. Build wealth for the long term using automated trading and transfers.